Blastomycosis a fungal infection is caused due to the organism known as Blastomyces dermatitidis. Blastomyces dermatitidis grows in wood and soil. When inhaled, the follicle of Blastomyces goes into the body through the air, majorly affecting the lungs and causing pneumonia. Then, the fungi spread to other parts of body through the bloodstream. Blastomycosis can affect any host; however, it is more extreme in people with weakened immune systems. Key factors propelling the growth of the blastomycosis market are an increase in the development of new medicine for the treatment of blastomycosis infection, a rise in the occurrence rate of chronic diseases such as tuberculosis, pneumonia, a non-infectious pulmonary disease which have resulted in increase in a number of blastomycosis patients, and increased adoption of azoles for the treatment of blastomycosis. Additionally, the rise in the incidence and prevalence rate of infectious diseases and the increase in the population of immunocompromised individuals augment the growth of this market. However, adverse reimbursements as well as complications of medicine and drugs may hamper the market growth

The global Blastomycosis Market is expected to be around US$ 257.7 million by 2028, growing at a CAGR of 3.8%.

The Blastomycosis Market has been segmented below:

Blastomycosis Market by Drug Type         

• Azoles
• Polyenes
• Others

Blastomycosis Market by Distribution Channel      

• Hospital and Clinical Pharmacy
• Online Pharmacy
• Retail Pharmacy

Blastomycosis Market by Formulation       

• Tablets
• Ointment
• Powder
• Liquid

Blastomycosis Market by Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

The Blastomycosis market by drug type is divided into Azoles, Polyenes and Others. Among which the azoles segment is holding the maximum share of the market. This is due to the surge in the number of fungal infections such as candidiasis, blastomycosis, and immunological disease and an increase in the awareness about the usage of azole drug for the treatment of blastomycosis. The rise of the azoles segment is also due to a rise in the usage of azole drugs in combination with another drug for a synergistic effect.

Accordance to the distribution channel, the market is bifurcated into Hospital and Clinical Pharmacy, Online Pharmacy and Retail Pharmacy. The Hospital and Clinical Pharmacy segment is accounted for the highest share in the market. The highest share of the segment is ascribed to the fact that a surge in demand for precise drugs as per the status of blastomycosis, and a rise in demand for consultation about the dosing of blastomycosis medicine.

As in the Formulation segmentation, the market is categorized as Tablets, Ointment, Powder and Liquid. The liquid segment holds the maximum share in the market. The factors such as the increased adoption of liquid formulations for the treatment of blastomycosis fungal infection, and the rise in the prevalence of fungal infection are responsible for the maximum share of the segment. Moreover, the surge in the need for quick onset of action in the treatment of blastomycosis has accelerated the growth of the liquid segment. 

The regional market is divided into North America, Europe, Asia Pacific and rest of the world. The North America region is the largest contributor in the market growth. This is due to the surge in the number of fungal infection cases, existence of leading players, advancements in healthcare in the region, strong healthcare infrastructure and increase in healthcare expenditure.

The expansion of the global blastomycosis market can be ascribed to the soaring cases of blastomycosis. In addition to this, the rising outdoor activities and poor diets across the globe are also projected to add to the market growth. In addition to these, factors that are believed to boost the market growth of blastomycosis treatment include the increase in poor lifestyles.

The market report provides the few notable companies include Pfizer Inc., johnson and johnson md&d, Merck and Company, CELON LABORATORIES LIMITED, Astellas Pharma Inc., Sanofi, GSK, Abbott Laboratories, Sun Pharmaceuticals Ltd and Cipla Ltd.

Henceforth, the blastomycosis market is likely to grow at a rapid pace. This is because of the fact that, it is estimated that blastomycosis disease is highly prevalent in the Africa and Middle East where the market for blastomycosis has a significant expansion.       

• This report defines, describes and forecasts the market by drug type, distribution channel, formulation and geography.
• This report gives complete details regarding the vital factors influencing the growth of the market.
• The report strategically analyzes the market in terms of individual growth trends, future prospects and the contribution of each segment to the market
• This report tracks and scrutinizes the competitive developments in market which include contracts & agreements, new product launches, expansions & investments, and partnerships and collaborations.